BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25166437)

  • 41. A case of light chain (AL) amyloidosis associated with IgD multiple myeloma (MM): clinical features, laboratory findings and outcome.
    Rizzi R; Miccolis R; Rinaldi E; Bonerba B; Rossini M; Manno C; Curci P; Specchia G; Liso V
    Amyloid; 2011 Jun; 18 Suppl 1():117-8. PubMed ID: 21838455
    [No Abstract]   [Full Text] [Related]  

  • 42. Free light chains ratio as a marker to estimate prognosis and survival in patients with multiple myeloma and primary amyloidosis.
    Radovic V; Mijuskovic Z; Tukic Lj; Djurdjevic P; Stojanovic J; Zlatkovic M
    J BUON; 2012; 17(1):110-5. PubMed ID: 22517703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Analysis of serum free light chains κ/λ ratio and heavy/light chain pairs of immunoglobulin to the stratification of multiple myeloma according to Mayo Stratification of Myeloma and Revised International Staging System].
    Ščudla V; Balcárková J; Lochman P; Vincová M; Pika T; Minařík J; Zapletalová J; Jarošová M
    Vnitr Lek; 2016 Apr; 62(4):269-80. PubMed ID: 27250604
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The prognostic value of baseline serum free light chain in immunoglobulin light-chain cardiac amyloidosis].
    Wang LM; Wang TT; Tian Y; Zhao L; Yang XC; Chen WM
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):47-53. PubMed ID: 32023754
    [No Abstract]   [Full Text] [Related]  

  • 45. The clinical spectrum of light chain myeloma. A study of 35 patients with special reference to the occurrence of amyloidosis.
    Stone MJ; Frendel EP
    Am J Med; 1975 May; 58(5):601-19. PubMed ID: 1130419
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Massive systemic amyloidosis associated with light-chain deposition disease.
    Troussard X; Hurault de Ligny B; Gallet B; Ganeval D; Mandard JC; Ryckelynck JP; Leporrier M
    Nephron; 1989; 52(2):139-43. PubMed ID: 2500613
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.
    Kyrtsonis MC; Vassilakopoulos TP; Kafasi N; Sachanas S; Tzenou T; Papadogiannis A; Galanis Z; Kalpadakis C; Dimou M; Kyriakou E; Angelopoulou MK; Dimopoulou MN; Siakantaris MP; Dimitriadou EM; Kokoris SI; Panayiotidis P; Pangalis GA
    Br J Haematol; 2007 May; 137(3):240-3. PubMed ID: 17408464
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Free light chains of immunoglobulins in amyloidosis.
    Sølling J; Sølling K
    Acta Med Scand; 1979; 206(4):283-7. PubMed ID: 116482
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein.
    Ishiguro K; Hayashi T; Yokoyama Y; Aoki Y; Onodera K; Ikeda H; Ishida T; Nakase H
    Intern Med; 2018 Mar; 57(6):783-788. PubMed ID: 29021469
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Free Light Chain Assays:  Freelite and N Latex in Diagnosis, Monitoring, and Predicting Survival in Light Chain Amyloidosis.
    Mahmood S; Wassef NL; Salter SJ; Sachchithanantham S; Lane T; Foard D; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Am J Clin Pathol; 2016 Jul; 146(1):78-85. PubMed ID: 27353767
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Prognostic factors in light chain amyloidosis].
    Jávorniczky NR; Bodó I; Masszi T; Mikala G
    Orv Hetil; 2015 Sep; 156(39):1577-84. PubMed ID: 26550915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Trends in Survival and Renal Recovery in Patients with Multiple Myeloma or Light-Chain Amyloidosis on Chronic Dialysis.
    Decourt A; Gondouin B; Delaroziere JC; Brunet P; Sallée M; Burtey S; Dussol B; Ivanov V; Costello R; Couchoud C; Jourde-Chiche N
    Clin J Am Soc Nephrol; 2016 Mar; 11(3):431-41. PubMed ID: 26728585
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monoclonal immunoglobulin deposition disease: light chain and light and heavy chain deposition diseases and their relation to light chain amyloidosis. Clinical features, immunopathology, and molecular analysis.
    Buxbaum JN; Chuba JV; Hellman GC; Solomon A; Gallo GR
    Ann Intern Med; 1990 Mar; 112(6):455-64. PubMed ID: 2106817
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Screening and differential diagnosis of renal light chain-associated diseases.
    Gerth J; Sachse A; Busch M; Illner N; Muegge LO; Gröne HJ; Wolf G
    Kidney Blood Press Res; 2012; 35(2):120-8. PubMed ID: 22056791
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thirteen treated of acute renal failure secondary to multiple myeloma with high cut off filters.
    Berni Wennekers A; Martín Azara MP; Dourdil Sahun V; Bergasa Liberal B; Ruiz Laiglesia JE; Vernet Perna P; Alvarez Lipe R
    Nefrologia; 2016; 36(4):418-26. PubMed ID: 27255910
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
    Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
    BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Strengths and weaknesses of methods for identifying monoclonal free light chains of Ig: examples from two cases with renal disease.
    Levinson SS
    Clin Chem Lab Med; 2016 Jun; 54(6):1039-43. PubMed ID: 26368046
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [A very unusual case of amyloidosis].
    Jouvin MH; Nochy D; Bruneval P; Guettier C; Druet P; Bariéty J
    Nephrologie; 1985; 6(3):159-62. PubMed ID: 3935940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Coexistent light chain deposition disease, light chain cast nephropathy, and vascular light chain amyloidosis in a patient with IgD lambda multiple myeloma.
    Lin ZS; Yu XJ; Qin AB; Liu MY; Wang SX; Zhou FD; Zhao MH
    Int Urol Nephrol; 2021 Aug; 53(8):1729-1731. PubMed ID: 33404783
    [No Abstract]   [Full Text] [Related]  

  • 60. Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
    Dimopoulos MA; Roussou M; Gavriatopoulou M; Psimenou E; Eleutherakis-Papaiakovou E; Migkou M; Matsouka C; Mparmparousi D; Gika D; Kafantari E; Ziogas D; Fotiou D; Panagiotidis I; Terpos E; Kastritis E
    Am J Hematol; 2016 May; 91(5):499-502. PubMed ID: 26890495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.